IBD Qorus: FAQs

What is IBD Qorus?

IBD Qorus is the Crohn's & Colitis Foundation's national initiative to improve the quality of care delivered to patients with Crohn's disease and ulcerative colitis, also known as inflammatory bowel diseases (IBD). The expanding program is creating a collaborative Learning Health System that empowers healthcare providers to share ideas and report quality metrics to a common platform, enabling researchers to compare patient experiences and treatment outcomes over time and across a variety of care settings. The studies made possible by IBD Qorus will lead to discoveries and insights to enhance health outcomes, as well as quality of life, for IBD patients.

What does IBD Qorus mean?

IBD Qorus' name is a variation of the word "chorus," to signify its goal of bringing together many voices and perspectives to form a more harmonious and stronger whole.

What are the goals of IBD Qorus?

IBD Qorus will:

  • Define standards of care for IBD;
  • Develop an implementation program to deliver and measure this care;
  • Conduct continuous evaluation and refinement of this process; and
  • Measure and improve its impact on IBD patient outcomes.

Why is IBD Qorus important?

A number of recent studies have shown a significant degree of variation in how physicians around the country diagnose and treat IBD. We know quality of care directly impacts the health and treatment outcomes for patients. While current treatments won't cure a patient's disease, optimal use of currently available treatments can help mitigate some of the symptoms and complications associated with IBD care. IBD Qorus brings together doctors and patients. Longer-term, continuous measurement, assessment, and refinement will maximize the strategy's impact and yield new insights for additional improvements.

The Affordable Care Act's National Healthcare Reform Initiative mandates more consistent and desirable outcomes for patients -- a goal which can only be achieved by the kind of comprehensive, systematic initiatives represented by IBD Qorus. Ultimately, the initiative will play a vital role in defining and disseminating the highest standards of care for IBD, and will contribute to the development of healthcare policies and strategies impacting IBD care worldwide. The result will be greater efficiencies and a reduction of costs in healthcare management.

How will IBD Qorus benefit patients?

IBD Qorus enables symptom tracking, self-management, and shared decision-making between patient and provider as well as facilitates their communication during and between visits. The initiative's innovative model of patient/provider co-facilitation of healthcare empowers patients to become more engaged and active in managing their care, and addressing other areas of concern.

IBD Qorus incorporates "care pathways" to address certain needs of IBD care. With a focus on issues that matter most to patients (e.g., IBD nutrition, anemia management, and urgent care), these standardized clinical care pathways are making a positive difference now to patient health outcomes and quality of life.

How will IBD Qorus benefit clinicians?

Healthcare providers participating in IBD Qorus will receive feedback on their patients' outcomes and learn from one another to improve their quality of care. Each of their patient's self-reported outcomes, concerns with symptoms, and disease activity assessments are integrated into a comprehensive, patient-centered tool, or "dashboard," to help inform decision-making and promote patient-provider co-facilitation of care. This technology enables patient population management that can help providers more easily access and identify patients at risk for specific outcomes, and move aggressively to provide the treatment they need.

In addition, findings from IBD Qorus are analyzed for all participating sites comparatively and collectively to promote the rapid spread of ideas and help in the assessment of best practices.

How will IBD Qorus benefit researchers?

IBD Qorus provides key clinical information that can synergize with other patient-centered research data and information to enable additional studies and early discoveries, particularly related to clinical questions. Its cohort will complement the extensive basic and translational research efforts to be supported by the Foundation's research exchange initiative, IBD Plexus®, which utilizes new technology to capture, organize, and share large amounts of data on individuals with IBD, and -- critically -- to link and mine this data for new insights.

Who is involved in IBD Qorus?

Supported by the Foundation, the two co-chairs of the project are Corey Siegel, MD, Director of the Dartmouth-Hitchcock Inflammatory Bowel Disease Center, and Gil Melmed, MD, Director of Clinical Inflammatory Bowel Disease at Cedars-Sinai Medical Center.

By 2018, IBD Qorus will partner with 30 community-based and large academic centers throughout the US.

How can a patient become involved?

Because IBD Qorus is still in its infancy, the only way a patient can become involved at this time is if their doctor is part of one of the 20 participating IBD centers. View our list of current centers.

How can a clinician become involved?

If a clinician is interested in learning more about the program, he/she can reach out to the IBD Qorus Director, Alandra Weaver at aweaver@ccfa.org.